Results 201 to 210 of about 180,170 (299)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol-Inspired Approach. [PDF]

Basic Clin Pharmacol Toxicol
Yu T, Wang C, Xie J, Wei Y, Cui H, Zhang H, Zhou F, Deng Z, Yang Y, Gu C.   +9 more
europepmc   +1 more source

Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

British Journal of Haematology, EarlyView.
Kenneth J. C. Lim, Elham Ashrafi, Cameron Wellard, Elizabeth M. Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Karen Dun, Rachel Cooke, Sabine Ringkowski, Adam Bryant, Georgia McCaughan, Erica Wood, Zoe McQuilten, P. Joy Ho, Hang Quach, Andrew Spencer   +18 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Haematologica, 2014
Neha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan, Mary Kwok, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant Tembhare, Constance Yuan, Maryalice Stetler-Stevenson, Jane Trepel, Richard Childs, Ola Landgren   +22 more
doaj   +1 more source

Testicular Plasmacytoma as the First Manifestation of Systemic Multiple Myeloma. [PDF]

Diagnostics (Basel)
Rodriguez-Parras P, Zambudio-Munuera A, Herraez-Marcos M, Gutierrez-Tejero F, Arrabal-Polo MA.   +4 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. [PDF]

Cancer Prev Res (Phila)
Fairfield H, Marinac CR, Hamidi H, Knox K, Nestor B, Marques-Mourlet C, Diaz G, Wong CV, Mishra AK, Schimelman A, Qiang YW, Karam M, Farrell M, Jachimowicz E, Stohn JP, Birmann BM, Cornelius P, Reagan MR.   +17 more
europepmc   +1 more source

Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials

British Journal of Haematology, EarlyView.
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Areti Voulomenou, Panagiotis Malandrakis, Efstathios Kastritis, Maria Gavriatopoulou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos   +7 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source